Gordon Van Slyke: A Trial Participant’s Inside Look at New Alzheimer’s Drug Leqembi

episode

Brain Talk | Being Patient for Alzheimer's Patients and Caregivers not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

7 Day Ceasefire Iran Offer, Trump-Xi AI Rivalry, More 10 min · 25 Sep 2026 · Bloomberg News Now

#685 - Joey Diaz 1h 59m · 25 Sep 2026 · This Past Weekend w/ Theo Von

NPR News: 09-25-2026 1AM EDT 5 min · 25 Sep 2026 · NPR News Now

1AM ET 09/25/2026 Newscast 3 min · 25 Sep 2026 · Fox News Hourly Update

The Same Yesterday, Today, and Forever 6 min · 25 Sep 2026 · Things Unseen with Sinclair B. Ferguson

The killer driver and member of Cock-Wall gang who poured bleach on elderly woman 22 min · 25 Sep 2026 · Crime World

Report any issue

Source

Recorded14 Jan 2023

Publisheranchor.fm ↗

Handlerec:7296436

Show notes

When Gordon Van Slyke, 75, decided to participate in the phase drug trials for Eisai and Biogen’s new monoclonal antibody drug Leqembi (lecanemab), it was his family history with Alzheimer’s that motivated him. Read more about his story: https://www.beingpatient.com/lecanemab-leqembi-trial-participant-story/

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in